 This is an open-label participants and researchers are aware about the treatment participants are receiving, multi-center when more than 1 hospital or medical school team work on a medical research study, drug-drug interaction DDI study of ibrutinib with the moderate and the strong CYP3A inhibitors erythromycin and voriconazole respectively in participants with B-cell malignancies including Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma CLLSLL, Follicular Lymphoma FL, Marginal Zone Lymphoma MZL, Waldenstroms Macroglobulinemia WM or Mantle Cell Lymphoma MCL. The study will consist of a Screening Phase 28 days, a Treatment Phase consisting of six 28-days cycles, and an End-of-Treatment EoT Visit within 30 days after the last dose of study drug. The study will consist of 2 Parts. In Part 1, extent of the DDI between ibrutinib at dose level of 140 milligram mg and CYP3A inhibitors will be assessed. After completion of Part 1 of the study, an interim analysis of all available PK and safety data will be conducted and Part 2 will only be performed if the observed drug interaction is less than anticipated based on current information. In Part 2, safety and PK of ibrutinib at dose level of 560 mg administered with CYP3A inhibitors will be assessed. Participants who continue to derive clinical benefit from ibrutinib treatment at the end of this study, and who are eligible to continue in the PCI-32765CAN3001 study NCT01804686 will end their participation in this trial, have an EoT visit completed, and will continue receiving ibrutinib as a part of the PCI-32765CAN3001 protocol. Participants safety will be monitored throughout the study. 